Aprea Therapeutics Inc (APRE)

US · Healthcare · Biotechnology

$0.52+4.50%

Last close · 2026-11-06

Latest quarter · ended 2026-09-30

Net profit

$-4.8M

EPS

$-0.09

EPS estimate

$-0.08

EPS came in at -0.09 against a street estimate of -0.08 — a miss of 12.5%.

Market cap

$7.2M

Forward P/E

0.0

P/B

0.17

Book value

$1.52

EPS (TTM)

$-0.95

52-week high

$1.32

52-week low

$0.41

50-day MA

$0.68

200-day MA

$0.75

Beta

1.69

Analysts rate Aprea Therapeutics Inc a strong buy (4 buy, 0 hold, 0 sell out of 4) with an average price target of $3.30.

Insiders

9.17%

Institutions

18.83%

Fund	Stake
AIGH Capital Management, LLC	8.07%
Nantahala Capital Management, LLC	3.27%
Vestal Point Capital LP	2.78%
Sphera Funds Management Ltd.	2.14%
Renaissance Technologies Corp	0.84%
Geode Capital Management, LLC	0.59%
Citadel Advisors Llc	0.47%
BNP Paribas Arbitrage, SA	0.36%

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aprea Therapeutics Inc — free to start.

Data updated 2026-11-07.